Corrigendum to 'clinical Outcomes Associated with the Emergency Treatment of Hyperkalaemia with Intravenous Insulin-Dextrose' [european Journal of Internal Medicine 95C (2021) 87-92].

The authors regret that the supplementary material was not published with their above article. The supplementary material has been published alongside this corrigendum for the readers’ reference. The authors apologise for any inconvenience caused. Download .docx (.05 MB) Help with docx files Clinical outcomes associated with the emergency treatment of hyperkalaemia with intravenous insulin-dextroseEuropean Journal of Internal MedicineVol. 95PreviewHyperkalaemia is a common, life-threatening electrolyte abnormality present in up to 10% of acute hospital admissions [1]. In patients receiving treatment with renin-angiotensin-aldosterone system (RAAS) blocking medication for heart failure, hypertension or diabetic nephropathy, the prevalence of hyperkalaemia exceeds 10% and in those with chronic kidney disease (CKD) (stage 4 or 5), this exceeds 20% [2]. Hyperkalaemia can result in fatal cardiac arrhythmias if not treated promptly. It typically requires in-hospital treatment and constitutes a medical emergency. Full-Text PDF Open Access